Effects of Xuezhikang and pravastatin on circulating endothelial progenitor cells in patients with essential hypertension
- PMID: 19688314
- DOI: 10.1007/s11655-009-0266-x
Effects of Xuezhikang and pravastatin on circulating endothelial progenitor cells in patients with essential hypertension
Abstract
Objective: To investigate the impacts of Xuezhikang (XZK) or pravastatin combined with antihypertensive drugs on circulating endothelial progenitor cells (CEPCs) in essential hypertensive (EH) patients.
Methods: Eighty-eight EH patients were enrolled into the study and randomly assigned to the antihypertensive drug treatment group (ATH group, 29 cases), the pravastatin treatment group (PRA group, 29 cases) and the Xuezhikang treatment group (XZK group, 30 cases). Patients in the 3 groups were treated with routine antihypertensive drugs. In addition, pravastatin and Xuezhikang were given to the patients in the PRA group and XZK group, respectively. After an eight-week treatment, CEPCs were counted using a laser scanning confocal microscope, and their proliferation function was evaluated by the MTT colorimetric assay and the adherent cell number was counted to estimate the adhesion function.
Results: After the treatment, CEPCs in the PRA group (116.60+/-5.70) and XZK group (114.40+/-6.55) was significantly higher than that in the ATH group (88.00+/-6.32, P<0.01). CEPCs proliferation capability and the adhesion function in the PRA group (0.406+/-0.016, 33.60+/-4.26) and XZK group (0.415+/-0.018, 34.30+/-3.77) were obviously superior to those in the ATH group (0.333+/-0.021, P<0.01; 23.30+/-3.19, P<0.01). No significant difference was found between the pravastatin group and the XZK group.
Conclusions: Combined use of XZK or pravastatin with the anti-hypertensive therapy could increase the CEPCs number and improve their function in EH patients with the blood pressure controlled by antihypertensive drugs, leading to benefits independent of pressure-lowering effects.
Similar articles
-
Effects of combined therapy of Xuezhikang Capsule and Valsartan on hypertensive left ventricular hypertrophy and heart rate turbulence.Chin J Integr Med. 2010 Apr;16(2):114-8. doi: 10.1007/s11655-010-0114-z. Epub 2010 May 16. Chin J Integr Med. 2010. PMID: 20473735 Clinical Trial.
-
[Effects of combined application of xuezhikang capsule with hypotensive drugs on arterial compliance and smoothness of the dynamic blood pressure].Zhongguo Zhong Xi Yi Jie He Za Zhi. 2010 May;30(5):463-6. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2010. PMID: 20681273 Clinical Trial. Chinese.
-
[Effects of xuezhikang at different doses on patients suffering from acute coronary syndrome after percutaneous coronary intervention].Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011 Dec;31(12):1607-10. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011. PMID: 22384544 Clinical Trial. Chinese.
-
Pravastatin decreases blood pressure in hypertensive and hypercholesterolemic patients receiving antihypertensive treatment.Circ J. 2006 Sep;70(9):1116-21. doi: 10.1253/circj.70.1116. Circ J. 2006. PMID: 16936421 Clinical Trial.
-
[Hypertension combined with atherosclerotic lesions in carotid arteries: should angiotensin converting enzyme inhibitors be prescribed?].Kardiologiia. 2005;45(12):99-102. Kardiologiia. 2005. PMID: 16353055 Review. Russian. No abstract available.
Cited by
-
Chinese patent medicine liu wei di huang wan combined with antihypertensive drugs, a new integrative medicine therapy, for the treatment of essential hypertension: a systematic review of randomized controlled trials.Evid Based Complement Alternat Med. 2012;2012:714805. doi: 10.1155/2012/714805. Epub 2012 Nov 11. Evid Based Complement Alternat Med. 2012. PMID: 23258998 Free PMC article.
-
Control strategy on hypertension in chinese medicine.Evid Based Complement Alternat Med. 2012;2012:284847. doi: 10.1155/2012/284847. Epub 2011 Dec 12. Evid Based Complement Alternat Med. 2012. PMID: 22194771 Free PMC article.
-
A systematic, updated review of Xuezhikang, a domestically developed lipid-lowering drug, in the application of cardiovascular diseases.Acta Pharm Sin B. 2024 Oct;14(10):4228-4242. doi: 10.1016/j.apsb.2024.05.011. Epub 2024 May 11. Acta Pharm Sin B. 2024. PMID: 39525586 Free PMC article. Review.
-
Ex vivo exposure of bone marrow from chronic kidney disease donor rats to pravastatin limits renal damage in recipient rats with chronic kidney disease.Stem Cell Res Ther. 2015 Apr 15;6(1):63. doi: 10.1186/s13287-015-0064-7. Stem Cell Res Ther. 2015. PMID: 25889756 Free PMC article.
-
Diabetes, Endothelial Dysfunction, and Vascular Repair: What Should a Diabetologist Keep His Eye on?Int J Endocrinol. 2015;2015:848272. doi: 10.1155/2015/848272. Epub 2015 May 18. Int J Endocrinol. 2015. PMID: 26089898 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials